Cantel Medical — Investor Presentation (June 2012)
22 slides from Cantel Medical's investor presentation, Jun 18, 2012
Slide 1: Infection Prevention & Control Matters
Cantel Medical Corp. (NYSE: CMN) Infection Prevention & Control Matters™ June 2012 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements. All forward-looking statements involve risks and uncertainties, including, without limitation, the risks detailed in the Company’s filin
Slide 2: Cantel Medical Corp. leader in infection prevention & control
2 Cantel Medical Corp. $385M NYSE Leader in Infection Prevention & Control1 Pure-play in a ~$45B Global Infection Prevention & Control Market (“IP&C”) Large, highly fragmented = growth opportunities 17 acquisitions since 2001 have re-shaped the company Recession-buffered with continued customer inve
Slide 3: Three Synergistic Platforms
3 Cantel Medical Corp. Three Synergistic Platforms Infection Prevention & Control Focus Healthcare & Life Sciences Orientation IP&C Device Management Endoscopy & Renal Dialysis Medivators/Byrne; Minntech Purification & Filtration Water Treatment & Therapeutic Filters Mar Cor Purification; Minntech D
Slide 4: Snapshot: By Product, Customer, Channel
4 Cantel Medical Corp. Snapshot: By Product, Customer, Channel Infection Prevention & Control Focus Healthcare & Life Sciences Orientation Renal / Dialysis Equipment, Sterilants, Consumables, Service Endoscopy Equipment, Disinfectants, Consumables, Service Dental Disposables Water Purification Equip
Slide 5: $45 Billion Global Market
5 Cantel Medical Corp. $45 Billion Global Infection Prevention & Control Market Healthcare Associated Infections (HAI’s) are the most common complication of hospital care2 Implementing existing prevention practices yields ~70% reduction in HAIs. Financial benefit ~$25B - $32B in medical cost savings
Slide 6: Healthcare Reform Creates Greater Emphasis in IP&C
6 Cantel Medical Corp. Healthcare Reform Creates Greater Emphasis in IP&C Financial Penalties to Hospitals1 Preventable Readmissions – Estimated $30 billion cost to the system Beginning 2012, Medicare will stop paying hospitals for preventable readmissions tied to heart failure or pneumonia Beginnin
Slide 7: Well-Balanced Portfolio with Emphasis on Endoscopy
7 Cantel Medical Corp. Well-Balanced Portfolio with Emphasis on Endoscopy All Other $16.89 4% Endoscopy $143.40 37% Dialysis $35.91 9% Healthcare Disposables $75.97 20% Endoscopy (BMI 1 qtrs preacquisition) $10.75 3% Water Purification & Filtration $101.65 27% Latest Twelve Months Ended April 30, 20
Slide 8: Significant Upside Growth Opportunities
8 Cantel Medical Corp. Significant Upside Growth Opportunities Acquisitions: 3 recent acquisitions, one in each core segment Byrne Medical has leadership position to drive a large, global market conversion to profitable disposable endoscopy components Continue solid integration and advancement on th
Slide 9: Significant Upside Growth Opportunities
9 Cantel Medical Corp. Significant Upside Growth Opportunities Substantial Sales & Marketing investments in core FY’09-FY’11 Substantial increase in R&D spending in FY’11 High-Margin Liquid Chemical Germicides (LCG) New chemistry development capabilities began mid-FY’10, accelerating in FY’11, to yi
Slide 10: Byrne Acquisition – Aug 1, 2011
10 Byrne Acquisition – Aug 1, 2011 Endoscopy: Facilitate Accelerated Global Growth Minntech subsidiary acquired the assets of Byrne Medical, Inc. for $89.4M in cash and $10.0M in stock, plus $10.0M potential earnout Pre-acquisition revenues of ~$38.6M and EBIT of $10.9M1 Complementary: Further bolst
Slide 11: Endoscopy Segment: Complementary Businesses
11 Medivators Plus Byrne Medical Endoscopy Segment: Complementary Businesses Intercept Wipes Veriscan Scope Buddy Intercept CER/DSD/ Advantage Rapicide Rapicide PA IN THE PROCEDURE ROOM Byrne Medical Products Treatment Room Physicians & Nurses Medivators Endoscope Reprocessing Products Principally i
Slide 12: Gambro Acquisition in FY'11
12 Gambro Acquisition in FY’11 Water Treatment Mar Cor Purification subsidiary acquired Gambro’s U.S. water treatment business (Oct 6, 2010) for $23.7M in cash. Pre-acquisition revenues of ~$14.0M. Strategic value akin to success of Mar Cor’s acquisition of GE’s Dialysis Water Business in March 2007
Slide 13: ConFirm Acquisition in FY'11
13 ConFirm Acquisition in FY’11 Healthcare Disposables Crosstex Int’l subsidiary acquired ConFirm Monitoring Systems’ sterility assurance business (Feb 14, 2011) for $7.5M in cash1. Pre-acquisition revenues of ~$4.0M. Product line extension to Crosstex’ key sterilization product category Position: #
Slide 14: Formula: Acquire, Improve Businesses, Repeat
14 Cantel Medical Corp. Formula: Acquire, Improve Businesses, Repeat CAGR% ’03-9M’12 17% 22% FY’11 and LTM PF12 are adjusted for the acquisition of Byrne Medical on August 1, 2011. $400 $375 $350 $325 $300 $275 $250 $225 $200 $175 $150 $125 $100 $75 $50 $25 $0 Phase I: Build Position; Grow EBITDAS [
Slide 15: Fragmented Nature of IP&C Market
15 Cantel Medical Corp. Fragmented Nature of Infection Prevention & Control 1 2 3 4 5 Disinfectants & Cleaners Disposables Masks / Headwear Air & Water Quality Protective Apparel Brushes Disposable kits / trays Face shields Air filtration systems Aprons / bibs / arm protectors Dispensers Disposable
Slide 16: Historical P&L Reveals Success of Acquisition Program
16 Cantel Medical Corp. Historical P&L Reveals Success of Acquisition Program 1 Reflects continuing operations and excludes any historical impact of Carsen Endoscopy & Surgical business. 2 Earnings before Interest, Taxes, Depreciation, Amortization, and Stock Compensation Expense. 3 Equivalent to “I
Slide 17: Capacity for Continued Investment
17 Cantel Medical Corp. Capacity for Continued Investment 2006 2007 2008 2009 2010 2011 Q3'12 $238.2 $263.7 $279.2 $277.9 $280.7 $321.4 $430.3 2.1:1 2.1:1 2.2:1 2.3:1 2.3:1 2.6:1 2.5:1 $140.8 $155.1 $168.7 $187.1 $209.4 $234.3 $266.4 0.27 0.37 0.35 0.23 0.10 0.10 0.38 1.4x 2.0x 1.8x 1.0x 0.4x 0.5x 1
Slide 18: Experienced Executive Team
18 Cantel Medical Corp. Experienced Executive Team Andrew A. Krakauer President & CEO Former President of Ohmeda Medical (Division of Instrumentarium/GE) Over 20 years of healthcare experience Joined Cantel in 2004 as COO Craig A. Sheldon SVP, Chief Financial Officer & Treasurer Formerly with Ernst
Slide 19: Strategic Objectives
19 Cantel Medical Corp. Strategic Objectives Remain Focused within Infection Prevention & Control Near-term build a profitable $500 Million Specialty Business...setting the strategy for $1 Billion Achieve accelerated growth and profits from the three recent acquisitions Invest in higher technology,
Slide 20: Strategic Evolution
20 Cantel Medical Corp. Cantel Medical Corp. Strategic Evolution FY’04 – FY’08: Acquire and Define Infection Prevention & Control (IPC) Portfolio FY’09 – FY’10: Substantial Operational and P&L Improvement, while Investing in Sales & Marketing FY’11: Leverage Sales & Marketing and Drive R&D Investmen
Slide 21: Summary
21 Cantel Medical Corp. Summary Growing ~$45B Global Market in Infection Prevention & Control Pure-play focus Fragmented nature creates opportunities for further growth and expansion $385M NYSE Specialty Infection Prevention & Control Leader1 Strong, recession-buffered core business with high future
Slide 22: Infection Prevention & Control Matters
Cantel Medical Corp. (NYSE: CMN) Infection Prevention & Control Matters™ CROSSTEX